一種新的腸道菌群代謝物與心血管疾病相關
作者:
小柯機器人發布時間:2020/3/9 12:49:33
美國克利夫蘭診所•勒納研究所Stanley L. Hazen課題組宣布他們發現與心血管疾病相關的腸道菌群代謝產物通過腎上腺素受體發揮功能。2020年3月5日,國際學術期刊《細胞》發表了這一成果。
對1162名受試者使用非靶向代謝組學,研究人員發現血漿代謝物(m / z = 265.1188)苯乙醯穀氨醯胺(PAGln),並在獨立隊列(n = 4,000名受試者)中發現其與心血管疾病(CVD)和重大不良心血管事件(心肌梗塞,中風或死亡)相關。在全血、分離的血小板和動脈損傷動物模型中,腸道菌群衍生代謝物PAGln可增強血小板活化相關的表型和促進血栓形成。對人類共生菌的功能和基因研究以及對無菌小鼠進行微生物定植的研究都表明微生物porA基因有利於食物中的苯丙氨酸轉化為苯乙酸,隨後宿主產生PAGln和苯乙醯基甘氨酸(PAGly)可促進培養血小板的反應性和血栓形成。使用遺傳和藥理學方法進行的功能獲得和功能喪失研究均表明,PAGln通過G蛋白偶聯受體(包括α2A,α2B和β2-腎上腺素受體)介導細胞事件。
因此,PAGln是一種促進CVD新的腸道菌群依賴性代謝產物,該代謝產物通過腎上腺素受體傳遞信號。
附:英文原文
Title: A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors
Author: Ina Nemet, Prasenjit Prasad Saha, Nilaksh Gupta, Weifei Zhu, Kymberleigh A. Romano, Sarah M. Skye, Tomas Cajka, Maradumane L. Mohan, Lin Li, Yuping Wu, Masanori Funabashi, Amanda E. Ramer-Tait, Sathyamangla Venkata Naga Prasad, Oliver Fiehn, Federico E. Rey, W.H. Wilson Tang, Michael A. Fischbach, Joseph A. DiDonato, Stanley L. Hazen
Issue&Volume: 2020/03/05
Abstract: Using untargeted metabolomics (n = 1,162 subjects), the plasma metabolite (m/z = 265.1188) phenylacetylglutamine (PAGln) was discovered and then shown in an independentcohort (n = 4,000 subjects) to be associated with cardiovascular disease (CVD) andincident major adverse cardiovascular events (myocardial infarction, stroke, or death).A gut microbiota-derived metabolite, PAGln, was shown to enhance platelet activation-relatedphenotypes and thrombosis potential in whole blood, isolated platelets, and animalmodels of arterial injury. Functional and genetic engineering studies with human commensals,coupled with microbial colonization of germ-free mice, showed the microbial porA gene facilitates dietary phenylalanine conversion into phenylacetic acid, with subsequenthost generation of PAGln and phenylacetylglycine (PAGly) fostering platelet responsivenessand thrombosis potential. Both gain- and loss-of-function studies employing geneticand pharmacological tools reveal PAGln mediates cellular events through G-proteincoupled receptors, including α2A, α2B, and β2-adrenergic receptors. PAGln thus representsa new CVD-promoting gut microbiota-dependent metabolite that signals via adrenergic receptors.
DOI: 10.1016/j.cell.2020.02.016
Source: https://www.cell.com/cell/fulltext/S0092-8674(20)30160-4
Cell:《細胞》,創刊於1974年。隸屬於細胞出版社,最新IF:36.216